Acute myeloid leukemia (AML) patients not in remission and beyond first or second complete remission are considered allogeneic stem cell transplant (SCT) candidates. We present 361 patients who underwent SCT from matched related or unrelated donors between 2005 and 2013. The purpose was to identify a subgroup of patients with active disease at the time of transplant that benefit. Cox proportional hazards regression analysis was used for univariate and multivariate analyses to predict overall survival (OS). Variables considered were age, sex, SWOG cytogenetic risk group, bone marrow (BM) and peripheral blood (PB) blast percentage, regimen intensity, and type of AML. At a median of 26 months after transplantation, OS, progression-free survival (PFS), non-relapse mortality, and relapse rates were 26, 24, 23, and 48%, respectively. In a univariate analysis, risk cytogenetics (p < 0.001) and BM blasts >4% (p = 0.006) or any blasts in PB (p < 0.001) indicated worse OS. In a multivariate analysis, patients with <5% BM blasts or absence of circulating blasts and good or intermediate risk cytogenetics had significantly superior OS (46%), PFS (44%), and disease progression at 3 years. Based on these findings, patients not in remission with good or intermediate risk cytogenetics and low blast counts should be considered for SCT.

1.
Burnett
AK
.
New induction and postinduction strategies in acute myeloid leukemia
.
Curr Opin Hematol
.
2012
Mar
;
19
(
2
):
76
81
.
[PubMed]
1065-6251
2.
Tian
H
,
Chen
GH
,
Xu
Y
, et al
Impact of pre-transplant disease burden on the outcome of allogeneic hematopoietic stem cell transplant in refractory and relapsed acute myeloid leukemia: a single-center study
.
Leuk Lymphoma
.
2014
;
•••
:
1
9
.
[PubMed]
1042-8194
3.
Döhner
H
,
Estey
EH
,
Amadori
S
,
Appelbaum
FR
,
Büchner
T
,
Burnett
AK
, et al;
European LeukemiaNet
.
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
.
Blood
.
2010
Jan
;
115
(
3
):
453
74
.
[PubMed]
0006-4971
4.
Kern
W
,
Haferlach
T
,
Schoch
C
,
Loffler
H
,
Gassmann
W
,
Heinecke
A
, et al
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial
.
Blood
.
2003
Jan
;
101
(
1
):
64
70
.
[PubMed]
0006-4971
5.
Forman
SJ
,
Schmidt
GM
,
Nademanee
AP
,
Amylon
MD
,
Chao
NJ
,
Fahey
JL
, et al
Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia
.
J Clin Oncol
.
1991
Sep
;
9
(
9
):
1570
4
.
[PubMed]
0732-183X
6.
Biggs
JC
,
Horowitz
MM
,
Gale
RP
,
Ash
RC
,
Atkinson
K
,
Helbig
W
, et al
Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy
.
Blood
.
1992
Aug
;
80
(
4
):
1090
3
.
[PubMed]
0006-4971
7.
Martin
PJ
,
Clift
RA
,
Fisher
LD
,
Buckner
CD
,
Hansen
JA
,
Appelbaum
FR
, et al
HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration
.
Blood
.
1988
Dec
;
72
(
6
):
1978
84
.
[PubMed]
0006-4971
8.
Feldman
EJ
,
Gergis
U
.
Management of refractory acute myeloid leukemia: re-induction therapy or straight to transplantation?
Curr Hematol Malig Rep
.
2012
Mar
;
7
(
1
):
74
7
.
[PubMed]
1558-8211
9.
Schmid
C
,
Schleuning
M
,
Schwerdtfeger
R
,
Hertenstein
B
,
Mischak-Weissinger
E
,
Bunjes
D
, et al
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation
.
Blood
.
2006
Aug
;
108
(
3
):
1092
9
.
[PubMed]
0006-4971
10.
Duval
M
,
Klein
JP
,
He
W
,
Cahn
JY
,
Cairo
M
,
Camitta
BM
, et al
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure
.
J Clin Oncol
.
2010
Aug
;
28
(
23
):
3730
8
.
[PubMed]
0732-183X
11.
Brown
RA
,
Wolff
SN
,
Fay
JW
,
Pineiro
L
,
Collins
RH
 Jr
,
Lynch
JP
, et al
High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group
.
Blood
.
1995
Mar
;
85
(
5
):
1391
5
.
[PubMed]
0006-4971
12.
Brown
RA
,
Wolff
SN
,
Fay
JW
,
Pineiro
L
,
Collins
RH
 Jr
,
Lynch
JP
, et al
High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: a study by the North American Marrow Transplant Group
.
Leuk Lymphoma
.
1996
Jul
;
22
(
3-4
):
271
7
.
[PubMed]
1042-8194
13.
Godder
KT
,
Hazlett
LJ
,
Abhyankar
SH
,
Chiang
KY
,
Christiansen
NP
,
Bridges
KD
, et al
Partially mismatched related-donor bone marrow transplantation for pediatric patients with acute leukemia: younger donors and absence of peripheral blasts improve outcome
.
J Clin Oncol
.
2000
May
;
18
(
9
):
1856
66
.
[PubMed]
0732-183X
14.
Goldman
FD
,
Rumelhart
SL
,
DeAlacron
P
,
Holida
MD
,
Lee
NF
,
Miller
J
, et al
Poor outcome in children with refractory/relapsed leukemia undergoing bone marrow transplantation with mismatched family member donors
.
Bone Marrow Transplant
.
2000
May
;
25
(
9
):
943
8
.
[PubMed]
0268-3369
15.
Sierra
J
,
Storer
B
,
Hansen
JA
,
Bjerke
JW
,
Martin
PJ
,
Petersdorf
EW
, et al
Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose
.
Blood
.
1997
Jun
;
89
(
11
):
4226
35
.
[PubMed]
0006-4971
16.
Michallet
M
,
Thomas
X
,
Vernant
JP
,
Kuentz
M
,
Socié
G
,
Espérou-Bourdeau
H
, et al
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM)
.
Bone Marrow Transplant
.
2000
Dec
;
26
(
11
):
1157
63
.
[PubMed]
0268-3369
17.
Greinix
HT
,
Reiter
E
,
Keil
F
,
Fischer
G
,
Lechner
K
,
Dieckmann
K
, et al
Leukemia-free survival and mortality in patients with refractory or relapsed acute leukemia given marrow transplants from sibling and unrelated donors
.
Bone Marrow Transplant
.
1998
Apr
;
21
(
7
):
673
8
.
[PubMed]
0268-3369
18.
Wong
R
,
Shahjahan
M
,
Wang
X
,
Thall
PF
,
De Lima
M
,
Khouri
I
, et al
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation
.
Biol Blood Marrow Transplant
.
2005
Feb
;
11
(
2
):
108
14
.
[PubMed]
1083-8791
19.
Hosing
C
,
Saliba
RM
,
Shahjahan
M
,
Estey
EH
,
Couriel
D
,
Giralt
S
, et al
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia
.
Bone Marrow Transplant
.
2005
Jul
;
36
(
2
):
157
62
.
[PubMed]
0268-3369
20.
Nemecek
ER
,
Gooley
TA
,
Woolfrey
AE
,
Carpenter
PA
,
Matthews
DC
,
Sanders
JE
.
Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia
.
Bone Marrow Transplant
.
2004
Nov
;
34
(
9
):
799
806
.
[PubMed]
0268-3369
21.
Oyekunle
AA
,
Kröger
N
,
Zabelina
T
,
Ayuk
F
,
Schieder
H
,
Renges
H
, et al
Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up
.
Bone Marrow Transplant
.
2006
Jan
;
37
(
1
):
45
50
.
[PubMed]
0268-3369
22.
Gupta
V
,
Tallman
MS
,
Weisdorf
DJ
.
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns
.
Blood
.
2011
Feb
;
117
(
8
):
2307
18
.
[PubMed]
0006-4971
23.
Zhang
WP
,
Yang
D
,
Song
XM
,
Ni
X
,
Chen
J
,
Chen
L
, et al
Allogeneic peripheral blood stem cell transplantation is a promising and safe choice for the treatment of refractory/relapsed acute myelogenous leukemia, even with a higher leukemia burden
.
Biol Blood Marrow Transplant
.
2013
Apr
;
19
(
4
):
653
60
.
[PubMed]
1083-8791
24.
Lee
SE
,
Cho
BS
,
Kim
JH
,
Yoon
JH
,
Shin
SH
,
Yahng
SA
, et al
Risk and prognostic factors for acute GVHD based on NIH consensus criteria
.
Bone Marrow Transplant
.
2013
Apr
;
48
(
4
):
587
92
.
[PubMed]
0268-3369
25.
Arai
S
,
Jagasia
M
,
Storer
B
,
Chai
X
,
Pidala
J
,
Cutler
C
, et al
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria
.
Blood
.
2011
Oct
;
118
(
15
):
4242
9
.
[PubMed]
0006-4971
26.
Slovak
ML
,
Kopecky
KJ
,
Cassileth
PA
,
Harrington
DH
,
Theil
KS
,
Mohamed
A
, et al
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study
.
Blood
.
2000
Dec
;
96
(
13
):
4075
83
.
[PubMed]
0006-4971
27.
Robak
T
,
Wrzesień-Kuś
A
.
The search for optimal treatment in relapsed and refractory acute myeloid leukemia
.
Leuk Lymphoma
.
2002
Feb
;
43
(
2
):
281
91
.
[PubMed]
1042-8194
28.
Pfeiffer
T
,
Schleuning
M
,
Mayer
J
,
Haude
KH
,
Tischer
J
,
Buchholz
S
, et al
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse
.
Haematologica
.
2013
Apr
;
98
(
4
):
518
25
.
[PubMed]
0390-6078
29.
Armand
P
,
Kim
HT
,
Logan
BR
,
Wang
Z
,
Alyea
EP
,
Kalaycio
ME
, et al
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation
.
Blood
.
2014
Jun
;
123
(
23
):
3664
71
.
[PubMed]
0006-4971
30.
Oran
B
,
Popat
U
,
Rondon
G
, et al
Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
2013
;19:214-20.
31.
Castro-Malaspina
H
,
Jabubowski
AA
,
Papadopoulos
EB
, et al
Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
2008
;14:458-68.
32.
Jabbour
E
,
Daver
N
,
Champlin
R
,
Mathisen
M
,
Oran
B
,
Ciurea
S
, et al
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy
.
Am J Hematol
.
2014
Apr
;
89
(
4
):
395
8
.
[PubMed]
0361-8609
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.